Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1041324 | 0.82 | — | — | |
| SCHEMBL15093055 | 0.78 | IDH1 (0.32) | — | |
| SCHEMBL1815634 | 0.78 | IDH1 (0.32) | — | |
| SCHEMBL1813470 | 0.78 | — | — | |
| SCHEMBL1812432 | 0.78 | — | — | |
| SCHEMBL131410 | 0.75 | NR1H3 (0.34) | SMN1; SMN2 | |
| SCHEMBL132258 | 0.73 | IDH1 (0.33) | — | |
| SCHEMBL602259 | 0.70 | — | — | |
| SCHEMBL1812282 | 0.69 | — | — | |
| SCHEMBL17489106 | 0.69 | PGK1 (0.41) | SMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3758706-A2 | WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME | The Regents Of The University Of Colorado (US) | 2021-01-06 | — | — | EP | claimed |
| US-20200405723-A1 | WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2020-12-31 | — | — | US | claimed |
| EP-3423446-B1 | NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS | Bayer Pharma AG (DE) | 2020-09-16 | — | — | EP | claimed |
| US-10435396-B2 | 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs | BAYER PHARMA AKTIEGESELLSCHAFT (DE) | 2019-10-08 | — | — | US | claimed |
| US-20190071432-A1 | NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-03-07 | — | — | US | claimed |
| EP-3423446-A1 | NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS | Bayer Pharma Aktiengesellschaft (DE) | 2019-01-09 | — | — | EP | claimed |
| WO-2017108744-A1 | NOVEL SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-29 | — | — | WO | claimed |
| CN-109153665-B | Novel 2-substituted indazoles, method for the production thereof, pharmaceutical preparations containing the same and use thereof for producing medicaments | 拜耳医药股份有限公司 | 2021-10-15 | — | — | CN | disclosed |
| EP-3758706-A2 | WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME | The Regents Of The University Of Colorado (US) | 2021-01-06 | — | — | EP | disclosed |
| US-20200405723-A1 | WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2020-12-31 | — | — | US | disclosed |
| EP-3423446-B1 | NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS | Bayer Pharma AG (DE) | 2020-09-16 | — | — | EP | disclosed |
| US-10435396-B2 | 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs | BAYER PHARMA AKTIEGESELLSCHAFT (DE) | 2019-10-08 | — | — | US | disclosed |
| US-20190071432-A1 | NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-03-07 | — | — | US | disclosed |
| US-20100063024-A1 | Dihydropyrazolopyrimidinone Derivatives | MERCK SHARP & DOHME LLC | 2010-03-11 | — | — | US | disclosed |
| CN-101432284-A | Dihydropyrazolopyrimidinone derivative | BANYU PHARMA CO LTD (JP) | 2009-05-13 | — | — | CN | disclosed |
| CN-101374844-A | Pyrrolopyridazinone compound | UBE INDUSTRIES (JP) | 2009-02-25 | — | — | CN | disclosed |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | UBE INDUSTRIES, LTD. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-2017278-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-21 | — | — | EP | disclosed |
| EP-1982986-A1 | PYRROLOPYRIDAZINONE COMPOUND | Ube Industries, Ltd. (JP) | 2008-10-22 | — | — | EP | disclosed |
| US-20070254892-A1 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405723-A1 | WEE1 KINASE INHIBITORS AND METHODS OF TREATING CANCER USING THE SAME | WEE1, WEE2, NME1 | SMN1; SMN2 4034/4885L3MBTL1 1416/4885 |
| US-10435396-B2 | 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs | CYP11B2, CYP19A1, CYP11B1 | SMN1; SMN2 1744/4885L3MBTL1 4657/4885 |
| US-20100063024-A1 | Dihydropyrazolopyrimidinone Derivatives | WEE1, WEE2, GRK3 | SMN1; SMN2 3943/4885L3MBTL1 1501/4885 |
| US-20070254892-A1 | Dihydropyrazolopyrimidinone derivatives | WEE1, WEE2, GRK3 | SMN1; SMN2 3943/4885L3MBTL1 1501/4885 |
| US-20090036453-A1 | Pyrrolopyridazinone Compound | CBR3, CBR1, CYC1 | SMN1; SMN2 4613/4885L3MBTL1 2482/4885 |
| US-20190071432-A1 | NEW 2-SUBSTITUTED INDAZOLES, METHODS FOR PRODUCING SAME, PHARMACEUTICAL PREPARATIONS THAT CONTAIN SAME, AND USE OF SAME TO PRODUCE DRUGS | CYP11B2, CYP19A1, CYP11B1 | SMN1; SMN2 1901/4885L3MBTL1 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.